<DOC>
	<DOCNO>NCT01213082</DOCNO>
	<brief_summary>The purpose study test hypothesis proton beam irradiation combine intravitreal anti-VEGF therapy safe potentially effective intravitreal anti-VEGF therapy alone eyes exudative age-related macular degeneration .</brief_summary>
	<brief_title>ProspectiveTrial Proton Beam Combined With Anti-VEGF Therapy Exudative Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>Radiation combine anti-VEGF therapy show synergistic treating cancer result sustain tumor regression . On-going clinical trial show potential synergism intravitreal anti-VEGF therapy epiretinal brachytherapy administer vitrectomy surgery treat eye exudative age-related macular degeneration ( eAMD ) . In study , test hypothesis radiation macula administer noninvasively via proton beam well-tolerated eye eAMD combine intravitreal anti-VEGF therapy combination therapy may act synergistically result sustain treatment effect eye eAMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Patient relate consideration Able maintain followup least 24 month . Women must postmenopausal without period least one year . Diagnosed Agerelated Macular Degeneration ( ARMD ) active subfoveal choroidal neovascular membrane ( CNVM ) , newly diagnose treat first dose antiVEGF therapy within 6 week enrollment Visual acuity 20/40 20/400 Lesion size &lt; 12 Disc Area Submacular hemorrhage le 75 % total lesion involve foveal center Submacular fibrosis le 25 % total lesion Candidate intravitreal antiVEGF therapy Subjects meet follow criterion exclude study : Prior enrollment study Pregnancy ( positive pregnancy test ) lactation Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Previous treatment Photodynamic Therapy ( PDT ) thermal laser study eye AntiVEGF therapy within 6 week Intravitreal subtenon 's Kenalog within 6 month Intraocular surgery within 3 month expect next 6 month Current plan participation experimental treatment wet AMD Other concurrent retinopathy optic neuropathy Other cause CNVM , i.e . myopic degeneration ocular histoplasmosis ( POHS ) Significant medium opacity preclude adequate view fundus exam , photography OCT History radiation therapy head study eye Diabetes mellitus hemoglobin A1c &gt; 6 Head tremor h/o claustrophobia preclude position proton irradiation Inability maintain steady fixation either eye History Malignancy treat within 5 year Allergy Fluorescein dye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Exudative Age-related Macular Degeneration</keyword>
	<keyword>Proton beam irradiation</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>anti-VEGF therapy</keyword>
</DOC>